Manufacturing & Marketing Approval of TREPIA: India Achieves Self-Reliance in Critical Radiological Emergency Medicine

DCGI Approval Marks a Major Milestone for Indigenous Development of Prussian Blue Insoluble Formulations

Prussian Blue Insoluble Capsules 0.5g Manufacturer in Mumbai
Prussian Blue Insoluble Capsules 0.5g

India has achieved a significant milestone in pharmaceutical innovation and national preparedness with the approval granted for manufacturing and marketing of Prussian Blue Insoluble formulations developed under the Technology Development Fund (TDF) initiative. The approval by the Drugs Controller General of India (DCGI) enables commercial manufacturing and distribution of these life-saving formulations by TAJ PHARMA INDIA LTD., Sarigam, Vapi, Gujarat.

This breakthrough represents an important advancement in strengthening India’s emergency preparedness infrastructure, particularly in responding to radiological and nuclear emergencies, while reinforcing the nation’s commitment towards technological self-reliance.


TREPIA: India’s Indigenous Solution for Radiological and Nuclear Emergencies

The approved formulations will be commercially available under the brand name TREPIA, representing a strategically important addition to India’s critical care pharmaceutical ecosystem.

TREPIA is specifically designed for:

  • Decontamination of radioactive Cesium exposure
  • Treatment of Thallium poisoning
  • Emergency preparedness during radiological incidents
  • Medical response systems during nuclear emergencies

The medicine contains Prussian Blue Insoluble formulations, recognized internationally as one of the essential medicines required during radiological contamination scenarios.

Its approval creates a domestic supply chain for a medicine that previously had limited availability and high strategic importance.


Technology Development Fund Accelerates Indigenous Pharmaceutical Innovation

The successful development of TREPIA demonstrates the effectiveness of India’s Technology Development Fund (TDF) program in encouraging collaboration between research institutions and private industry.

Under this initiative:

  • Advanced technologies developed by government laboratories are transferred to industry partners
  • Domestic manufacturing capabilities are strengthened
  • Strategic healthcare products become commercially accessible
  • Dependence on imported critical medicines is reduced

The collaboration successfully transformed research-driven technology into a commercially viable pharmaceutical product with national importance.


DRDO and INMAS Technology Powers Critical Drug Development

The scientific foundation behind TREPIA originates from the Institute of Nuclear Medicine & Allied Sciences (INMAS), Delhi, a laboratory operating under the Defence Research & Development Organisation (DRDO).

INMAS has extensive expertise in:

Radiation Medicine

Developing technologies and countermeasures for radiation exposure management.

Nuclear Emergency Preparedness

Creating solutions for civilian and defence applications during nuclear incidents.

Advanced Medical Countermeasure Research

Supporting national capabilities for disaster response and specialized healthcare requirements.

The successful technology transfer from INMAS to industry demonstrates how research institutions can accelerate commercialization of strategically important medicines.


Why Prussian Blue Insoluble Formulations Are Critical Medicines

Prussian Blue Insoluble is globally recognized as a highly specialized medical countermeasure.

How It Works

The formulation works by:

  • Binding radioactive Cesium isotopes inside the gastrointestinal tract
  • Preventing reabsorption into the body
  • Accelerating elimination through natural excretion pathways
  • Reducing internal radiation exposure

Similarly, the medicine assists in:

  • Binding Thallium compounds
  • Enhancing removal from the body
  • Lowering toxic accumulation

This mechanism significantly reduces long-term health complications associated with radioactive contamination.


WHO Recognition Highlights Strategic Importance

The importance of Prussian Blue formulations extends beyond national requirements.

The medicine is listed among critical medical countermeasures recommended during:

  • Nuclear accidents
  • Radiological contamination events
  • Industrial radiation incidents
  • Emergency preparedness stockpiles
  • National disaster response programs

The availability of domestically manufactured TREPIA strengthens healthcare resilience and emergency response capabilities.


TAJ PHARMA INDIA LTD. Expands Strategic Manufacturing Capabilities

The approval awarded to TAJ PHARMA INDIA LTD. demonstrates the growing capability of Indian pharmaceutical manufacturers to produce highly specialized formulations.

The manufacturing infrastructure at Sarigam, Gujarat supports:

Advanced Pharmaceutical Manufacturing

Production systems designed for high-quality pharmaceutical output.

Regulatory Compliance

Manufacturing practices aligned with stringent quality requirements.

Scalable Production

Capacity expansion potential for national requirements and future international demand.

Specialized Healthcare Products

Support for complex formulations with strategic healthcare applications.

The achievement further positions Indian pharmaceutical companies as partners in national healthcare security.


DCGI Approval Strengthens India’s Emergency Preparedness Framework

The approval issued by DCGI creates multiple benefits for healthcare systems and emergency response infrastructure.

Improved Medicine Accessibility

Domestic production reduces dependence on international procurement.

Faster Emergency Response

Local manufacturing improves supply chain responsiveness.

Strategic Stockpile Development

Supports creation of national emergency medicine reserves.

Reduced Supply Vulnerability

Domestic manufacturing minimizes risks associated with global disruptions.

The availability of TREPIA creates a stronger medical preparedness ecosystem for future contingencies.


A Major Step Toward Aatmanirbhar Bharat

The successful commercialization of TREPIA directly supports India’s broader objective of strengthening indigenous innovation and manufacturing capabilities.

The initiative contributes toward:

  • Reducing import dependency
  • Promoting technology commercialization
  • Supporting domestic pharmaceutical innovation
  • Strengthening national healthcare resilience
  • Expanding strategic manufacturing capabilities

The achievement demonstrates how coordinated collaboration between research institutions, regulators, and industry can generate impactful outcomes.


Future Opportunities for Critical Care Pharmaceutical Manufacturing

The approval of TREPIA may accelerate future investment into specialized therapeutic areas including:

Radiation Medicine

Growing requirements for specialized emergency medical products.

Disaster Preparedness Solutions

Expanding stockpiling and emergency infrastructure.

Specialized Toxicology Treatments

Development of advanced countermeasure formulations.

Strategic Healthcare Manufacturing

Strengthening domestic production of high-priority medicines.

This development may create new opportunities for expanding India’s leadership in specialized pharmaceutical manufacturing.


The approval granted for manufacturing and marketing TREPIA represents more than a regulatory milestone—it reflects the successful convergence of scientific research, industrial capability, and national priorities.

The development of indigenous Prussian Blue Insoluble formulations under the Technology Development Fund initiative demonstrates India’s ability to create strategic healthcare solutions capable of supporting national preparedness requirements.

With DCGI approval now secured, TREPIA strengthens India’s capability to respond effectively to radiological and nuclear emergencies while advancing the broader vision of self-reliance, innovation, and pharmaceutical leadership.